Evidence map›Paper›PMID 30420654›Full record

ArticleCell death & disease2018

Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage.

Yun-Hee Bae, Hyejin Joo, Jinhyun Bae, Seung Jae Hyeon, Song Her, Eunhwa Ko, Hwan Geun Choi, Hoon Ryu, Eun-Mi Hur, Youngmin Bu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Benzoate Drugs for Traumatic Brain Injury.Journal of clinical & experimental immunology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Yun-Hee BaeDepartment of Neuroscience, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Hyejin JooDepartment of Science in Korean medicine, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Jinhyun BaeDepartment of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
Seung Jae HyeonCenter for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
Song HerKorea Basic Science Institute, Seoul, 03759, Republic of Korea.
Eunhwa KoNew Drug development center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, 41061, Republic of Korea.
Hwan Geun ChoiNew Drug development center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, 41061, Republic of Korea.
Hoon RyuCenter for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
Eun-Mi HurDepartment of Neuroscience, College of Veterinary Medicine, Research Institute for Veterinary Science, and BK21 PLUS Program for Creative Veterinary Science Research, Seoul National University, Seoul, 08826, Republic of Korea.
Youngmin BuDepartment of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea. ymbu@khu.ac.kr.
Byoung Dae LeeDepartment of Neuroscience, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea. bdaelee@khu.ac.kr.
Kyung Hee University · KRDaegu-Gyeongbuk Medical Innovation Foundation · KRBoston University · USKorea Basic Science Institute · KRKorea Institute of Brain Science · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2), originally identified as a causative genetic factor in Parkinson's disease, is now associated with a number of pathologies. Here, we show that brain injury induces a robust expression of endogenous LRRK2 and suggest a role of LRRK2 after injury. We found that various in vitro and in vivo models of traumatic brain injury (TBI) markedly enhanced LRRK2 expression in neurons and also increased the level of hypoxia-inducible factor (HIF)-1α. Luciferase reporter assay and chromatin immunoprecipitation revealed direct binding of HIF-1α in LRRK2 proximal promoter. We also found that HIF-1α-dependent transcriptional induction of LRRK2 exacerbated neuronal cell death following injury. Furthermore, application of G1023, a specific, brain-permeable inhibitor of LRRK2, substantially prevented brain tissue damage, cell death, and inflammatory response and alleviated motor and cognitive defects induced by controlled cortical impact injury. Together, these results suggest HIF-1α-LRRK2 axis as a potential therapeutic target for brain injury.

Indexed as

Transcription, GeneticAnimalsApoptosisBase SequenceBrain Injuries, TraumaticCerebral CortexFemaleGene Expression RegulationHumansHypoxia-Inducible Factor 1, alpha SubunitLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MiceMice, Inbred ICRMitochondriaNeuronsNeuroprotective AgentsHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Lrrk2 protein, mouseNeuroprotective AgentsProtein Kinase Inhibitors

Identifiers

PMID30420654
PMCPMC6232134
OpenAlexW2900617869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.